JNK-deficiency enhanced oncolytic vaccinia virus replication and blocked activation of double-stranded RNA-dependent protein kinase

Cancer Gene Therapy

Volumn 15, Issue 9, 2008, Pages 616-624

  Hu, W ^a,b   Hofstetter, W ^a   Guo, W ^a   Li, H ^a   Pataer, A ^a   Peng, H H ^a   Guo, Z S ^c   Bartlett, D L ^c   Lin, A ^d   Swisher, S G ^a   Fang, B ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b ZHEJIANG UNIVERSITY   (China)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

Apoptosis; Cancer; JNK; PKR; Virotherapy; Virus replication

Indexed keywords

JANUS KINASE; JANUS KINASE INHIBITOR; PROTEIN KINASE R; STRESS ACTIVATED PROTEIN KINASE;

ADENOVIRUS; ARTICLE; CELL KILLING; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME DEFICIENCY; GENE TARGETING; HUMAN; HUMAN CELL; INFECTION SENSITIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; VACCINIA VIRUS; VIROTHERAPY; VIRUS REPLICATION;

ANIMALS; CELL LINE, TUMOR; EIF-2 KINASE; ENZYME ACTIVATION; EUKARYOTIC INITIATION FACTORS; GENE EXPRESSION REGULATION; HELA CELLS; HUMANS; MICE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASE 8; MITOGEN-ACTIVATED PROTEIN KINASE 9; ONCOLYTIC VIRUSES; PHOSPHORYLATION; RNA, DOUBLE-STRANDED; VACCINIA VIRUS; VIRUS REPLICATION;

ADENOVIRIDAE; VACCINIA VIRUS;

EID: 49549125399     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2008.32     Document Type: Article

References (39)

1. Cebere I, Dorrell L, McShane H, Simmons A, McCormack S, Schmidt C et al. Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine 2006; 24: 417-425.
2. Moss B. Vaccinia virus: a tool for research and vaccine development. Science 1991; 252: 1662-1667.
3. Harrington LE, Most RR, Whitton JL, Ahmed R. Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope. J Virol 2002; 76: 3329-3337.
4. Guo ZS, Bartlett DL. Vaccinia as a vector for gene delivery. Expert Opin Biol Ther 2004; 4: 901-917.
5. Guo ZS, Naik A, O'Malley ME, Popovic P, Demarco R, Hu Y et al. The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. Cancer Res 2005; 65: 9991-9998.
6. Thorne SH, Hwang TH, Kirn DH. Vaccinia virus and oncolytic virotherapy of cancer. Curr Opin Mol Ther 2005; 7: 359-365.
7. Hruby DE, Lynn DL, Kates JR. Vaccinia virus replication requires active participation of the host cell transcriptional apparatus. Proc Natl Acad Sci USA 1979; 76: 1887-1890.
8. Lee SB, Esteban M. The interferon-induced double-stranded RNA-activated human p68 protein kinase inhibits the replication of vaccinia virus. Virology 1993; 193: 1037-1041.
9. Karupiah G, Xie QW, Buller RM, Nathan C, Duarte C, MacMicking JD. Inhibition of viral replication by interferon-gamma-induced nitric oxide synthase. Science 1993; 261: 1445-1448.
10. Melkova Z, Esteban M. Interferon-gamma severely inhibits DNA synthesis of vaccinia virus in a macrophage cell line. Virology 1994; 198: 731-735.
11. Diaz-Guerra M, Rivas C, Esteban M. Inducible expression of the 2-5A synthetase/RNase L system results in inhibition of vaccinia virus replication. Virology 1997; 227: 220-228.
12. McLean TI, Bachenheimer SL. Activation of cJUN N-terminal kinase by herpes simplex virus type 1 enhances viral replication. J Virol 1999; 73: 8415-8426.
13. Holloway G, Coulson BS. Rotavirus activates JNK and p38 signaling pathways in intestinal cells, leading to AP-1-driven transcriptional responses and enhanced virus replication. J Virol 2006; 80: 10624-10633.
14. Clarke P, Meintzer SM, Wang Y, Moffitt LA, Richardson-Burns SM, Johnson GL et al. JNK regulates the release of proapoptotic mitochondrial factors in reovirus-infected cells. J Virol 2004; 78: 13132-13138.
15. Hirasawa K, Kim A, Han HS, Han J, Jun HS, Yoon JW. Effect of p38 mitogen-activated protein kinase on the replication of encephalomyocarditis virus. J Virol 2003; 77: 5649-5656.
16. Rahaus M, Desloges N, Wolff MH. Replication of varicella-zoster virus is influenced by the levels of JNK/SAPK and p38/MAPK activation. J Gen Virol 2004; 85: 3529-3540.
17. Teraishi F, Zhang L, Guo W, Dong F, Davis JJ, Lin A et al. Activation of c-Jun NH2-terminal kinase is required for gemcitabine's cytotoxic effect in human lung cancer H1299 cells. FEBS Lett 2005; 579: 6681-6687.
18. Teraishi F, Wu S, Sasaki J, Zhang L, Davis JJ, Guo W et al. JNK1-dependent antimitotic activity of thiazolidin compounds in human non-small-cell lung and colon cancer cells. Cell Mol Life Sci 2005; 62: 2382-2389.
19. Deng Y, Ren X, Yang L, Lin Y, Wu X. A JNK-dependent pathway is required for TNFalpha-induced apoptosis. Cell 2003; 115: 61-70.
20. Tournier C, Hess P, Yang DD, Xu J, Turner TK, Nimnual A et al. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 2000; 288: 870-874.
21. Verheij M, Bose R, Lin XH, Yao B, Jarvis WD, Grant S et al. Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature 1996; 380: 75-79.
22. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995; 270: 1326-1331.
23. Liu J, Minemoto Y, Lin A. c-Jun N-terminal protein kinase 1 (JNK1), but not JNK2, is essential for tumor necrosis factor alpha-induced c-Jun kinase activation and apoptosis. Mol Cell Biol 2004; 24: 10844-10856.
24. Yang YL, Reis LF, Pavlovic J, Aguzzi A, Schafer R, Kumar A et al. Deficient signaling in mice devoid of double-stranded RNA-dependent protein kinase. EMBO J 1995; 14: 6095-6106.
25. Fang B, Ji L, Bouvet M, Roth JA. Evaluation of GAL4/TATA in vivo. Induction of transgene expression by adenovirally mediated gene codelivery. J Biol Chem 1998; 273: 4972-4975.
26. Wojtaszek PA, Heasley LE, Siriwardana G, Berl T. Dominant-negative c-Jun NH2-terminal kinase 2 sensitizes renal inner medullary collecting duct cells to hypertonicity-induced lethality independent of organic osmolyte transport. J Biol Chem 1998; 273: 800-804.
27. Zheng C, Xiang J, Hunter T, Lin A. The JNKK2-JNK1 fusion protein acts as a constitutively active c-Jun kinase that stimulates c-Jun transcription activity. J Biol Chem 1999; 274: 28966-28971.
28. Pauwels B, Korst AE, De Pooter CM, Pattyn GG, Lambrechts HA, Baay MF et al. Comparison of the sulforhodamine B assay and the clonogenic assay for in vitro chemoradiation studies. Cancer Chemother Pharmacol 2003; 51: 221-226.
29. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 2001; 98: 13681-13686.
30. Teraishi F, Wu S, Zhang L, Guo W, Davis JJ, Dong F et al. Identification of a novel synthetic thiazolidin compound capable of inducing c-Jun NH2-terminal kinase-dependent apoptosis in human colon cancer cells. Cancer Res 2005; 65: 6380-6387.
31. Rice AP, Kerr IM. Interferon-mediated, double-stranded RNA-dependent protein kinase is inhibited in extracts from vaccinia virus-infected cells. J Virol 1984; 50: 229-236.
32. Kawagishi-Kobayashi M, Silverman JB, Ung TL, Dever TE. Regulation of the protein kinase PKR by the vaccinia virus pseudosubstrate inhibitor K3L is dependent on residues conserved between the K3L protein and the PKR substrate eIF2alpha. Mol Cell Biol 1997; 17: 4146-4158.
33. Meurs E, Chong K, Galabru J, Thomas NS, Kerr IM, Williams BR et al. Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon. Cell 1990; 62: 379-390.
34. Williams BR. Signal integration via PKR. Sci STKE 2001; 2001: RE2-.
35. Li S, Peters GA, Ding K, Zhang X, Qin J, Sen GC. Molecular basis for PKR activation by PACT or dsRNA. Proc Natl Acad Sci USA 2006; 103: 10005-10010.
36. Patel RC, Sen GC. PACT, a protein activator of the interferon-induced protein kinase, PKR. EMBO J 1998; 17: 4379-4390.
37. Williams BR. PKR; a sentinel kinase for cellular stress. Oncogene 1999; 18: 6112-6120.
38. Goh KC, deVeer MJ, Williams BR. The protein kinase PKR is required for p38 MAPK activation and the innate immune response to bacterial endotoxin. EMBO J 2000; 19: 4292-4297.
39. Chu WM, Ostertag D, Li ZW, Chang L, Chen Y, Hu Y et al. JNK2 and IKKbeta are required for activating the innate response to viral infection. Immunity 1999; 11: 721-731.